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Abstract. Advanced prostate cancer has signiﬁcant long-term morbidity, and there is a growing interest in
alternative and complimentary forms of therapy that will improve the outcomes of patients. Azadirachta
indica (common name: neem) contains multiple active compounds that have potent anti-inﬂammatory
and anticancer properties. The present study investigates the novel targets of the anticancer activity of
ethanol extract of neem leaves (EENL) in vitro and evaluates the in vivo efﬁcacy in the prostate cancer
models. Analysis of the components in the EENL by mass spectrometry suggests the presence of 2′,3′-
dehydrosalannol, 6-desacetyl nimbinene, and nimolinone. Treatment of C4-2B and PC-3M-luc2 prostate
cancer cells with EENL inhibited the cell proliferation. Genome-wide expression proﬁling, using
oligonucleotide microarrays, revealed genes differentially expressed with EENL treatment in prostate
cancer cells. Functional analysis unveiled that most of the up-regulated genes were associated with cell
death, and drug metabolism, and the down-regulated genes were associated with cell cycle, DNA
replication, recombination, and repair functions. Quantitative PCR conﬁrmed signiﬁcant up-regulation of
40 genes and immunoblotting revealed increase in the protein expression levels of HMOX1, AKR1C2,
AKR1C3, and AKR1B10. EENL treatment inhibited the growth of C4-2B and PC-3M-luc2 prostate
cancer xenografts in nude mice. The suppression of tumor growth is associated with the formation of
hyalinized ﬁbrous tumor tissue and the induction of cell death by apoptosis. These results suggest
that EENL-containing natural bioactive compounds could have potent anticancer property and the
regulation of multiple cellular pathways could exert pleiotrophic effects in prevention and treatment
of prostate cancer.
KEY WORDS: gene expression proﬁles; neem leaf extract; therapeutic targets and prostate cancer;
tumor models;
INTRODUCTION
Prostate cancer is one of the most prevalent malignant
neoplasms and the third leading cause of cancer-related death
of men of the Western countries (1). The mainstay of
treatment of advanced prostate cancer is focused on suppres-
sion of intraprostatic testosterone and dihydrotestosterone
(DHT) actions (2). However, after an initial response,
therapy-resistant clones can appear and result in cancer
progression and metastasis with high mortality (3). First-line
chemotherapy for advanced prostate cancer has not dem-
onstrated signiﬁcant improvement in overall survival but
could provide disease control and palliation (4). Novel
treatment modalities are therefore needed to treat hormone-
resistant tumors and to prevent the progression of hormone-
sensitive prostate cancer to hormone-refractory stage. The
search for compounds with few or no adverse effects that
will preventcancerprogressionandprotect againstthe adverse
biological effects of chemotherapeutic agents as compared
with the agents currently in use is therefore of greatest
relevance.
Herbal plants and plant-derived medicines have been
used as the source of potential anticancer agents in traditional
cultures all over the world and are becoming increasingly
popular in modern society (5). The potential natural product-
derived anticancer agents are known to possess various
bioactive phytochemicals. Terpenoids constitute one of the
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40,000 individual compounds of both primary and secondary
metabolisms (6). Many herbal plants contain terpenoids, and
several terpenoids have been shown to be available for
pharmaceutical applications, for example, artemisinin and
taxol as malaria and cancer medicines, respectively (7). Neem
is one such medicinal plant, the extract of which has been
used for thousands of years for most acute and chronic
diseases in India and Africa. The major biologically active
constituents of neem leaves are limonoids, triterpenoids,
nonterpenoids, phenolics, ﬂavonoids, and meliacins (8,9),
potentially targeting multiple signaling pathways of cancer
cells (10–12). Extract of neem leaves have been reported to
be non-toxic, non-mutagenic, and found to possess immuno-
modulatory, anti-inﬂammatory, and anticarcinogenic proper-
ties (13,14). Neem leaf glycoprotein exhibited antitumor
activity by activation of cytotoxic T lymphocytes and natural
killer cells in patients with head and neck squamous cell
carcinoma (15). To date, there is only one report of neem on
prostate cancer which showed the in vitro inhibition of PC-3
cell proliferation and Bcl-2 expression after neem treatment
(12). No further studies of any neem compounds or extracts
were reported on prostate cancer. The above reasoning
promoted use to explore the antitumor effects of neem leaves
on human prostate cancer cells which could lead to future
clinical trials for prostate cancer patients.
Our study is designed to identify and evaluate the
molecular targets of anticancer activities of ethanol extract
of neem leaves (EENL) in prostate cancer models. We
performed liquid chromatography/time-of-ﬂight mass spec-
trometry (LC/TOF-MS) analyses to identify the components
in the EENL. To unravel the molecular effects of EENL in
androgen-refractory metastatic prostate cancer cells, we used
gene expression microarrays and identiﬁed target genes
regulated in prostate cancer cells after treatment with EENL.
We then conﬁrmed the alterations in mRNA and protein
expression levels of the genes. The antitumor activity of
EENL was further evaluated in the prostate cancer mouse
models using C4-2B and PC-3M-luc2 cells.
MATERIALS AND METHODS
Ethanol Extraction of Neem Leaves
Neem tree leaves harvested during the summer season
were obtained from Neem Tree Farms (Brandon, FL). Neem
leaves of the same age were washed with distilled water,
air-dried, and 10 g of pulverized leaves were passed through a
Soxhlet extractor for 4 h with 250 mL of 100% ethanol. All
the alcohol was evaporated at low temperature using
Rotavapor R-200 (Buchi, New Castle, DE) under vacuum.
The residue was freeze-dried and yielded approximately 1.0 g
of the dried powder. This extracted powder was stored
at −20°C. An aliquot of 100 mg of this powder was dissolved
in 250 μL of dimethyl sulfoxide (DMSO) plus 250 μL of 100%
ethanol (stock 200 μg/μL). The suspension was ﬁltered using
a 0.22 μm ﬁlter and stored at −20°C. The stock solution was
further diluted with ethanol for all the experiments. The ﬁnal
concentration of DMSO in the culture medium never
exceeded 0.01%. The effect of the extract on cell viability
and gene expression levels described below were assessed to
standardize the method of extraction. We obtained consistent
results with different lots of the extract.
LC/TOF-MS Analyses
High-performance liquid chromatography (HPLC)-grade
acetonitrile, water, isopropanol, and methanol were
purchased from Burdick and Jackson (Muskegon, Michigan).
Formic acid was obtained from Fluka (Fluka/Sigma-Aldrich
St. Louis, Missouri). 2′,3′-dehydrosalannol, a known compo-
nent of neem leaves, was obtained from the Asthagiri Herbal
Research Foundation (Channai, Tamil Nadu, India) for use as
a standard. The analytes were separated using an HPLC
system (Agilent series 1100, Agilent Technologies, Palo Alto,
CA) equipped with a reversed-phase C18 analytical column
(Zorbax Eclipse 300SB-C18 1.0×150 mm, 3.5 mm). The
column temperature was maintained at 45°C. The makeup
of the LC mobile phases was as follows: mobile phase A
water:acetonitrile:isopropanol:formic acid (98:1:1:0.1), mobile
phase B acetonitrile:water:isopropanol:formic acid
(80:10:10:0.1). Separation was achieved by using a linear
gradient from 5% B to 100% B over 45 min. The ﬂow rate
was 0.05 mL/min, and 5 μL injections were made of the
2 μg/μL standards and neem extract solutions dissolved in
mobile phase A. The HPLC system was connected to a
time-of-ﬂight mass spectrometer (MSD-TOF, Agilent
Technologies) equipped with an electrospray interface.
The instrument was operated under the following operating
parameters: capillary 4,000 V, nebulizer 15 psig, drying gas
7 L/min, gas temperature 325°C, fragmentor 225 V, skimmer
60 V, Oct dc1 37.5 V, Oct rf V 250 V. The instrument was
calibrated using the calibrant mixture provided by the manu-
facturer over the 50–3200 m/z range. The scan range for data
acquisition was 300–1,500 m/z range.
Cell Line and Cell Culture
C4-2B, originated from LNCaP cell line, is a castration-
resistant prostate cancer cell line purchased from ViroMed
Laboratories (Minnetonka, MN). PC-3M-luc2, originated
from PC3, is a luciferase-expressing metastatic prostate
cancer cell line which was stably transfected with ﬁreﬂy
luciferase gene (luc2), was purchased from Caliper
LifeScience (Hopkinton, MA). C4-2B cells were grown in
RPMI 1640 medium and PC-3M-luc2 cells were grown in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) media as
described previously (16).
Cell Viability Assay
C4-2B and PC-3M-luc2 cells were seeded into 96-well
plates at a density of 3×10
3 and 1.5×10
3 per well respectively,
as previously described (17). C4-2B cells were treated with
5.0 to 15.0 μg/mL and PC-3M-luc2 cells were treated with 5.0
to 50.0 μg/mL of the EENL or with the vehicle control
(ethanol+DMSO) for 24, 48, and 72 h. Cell viability was then
determined by the colorimetric MTS assay using CellTiter 96
AQueous One Solution Proliferation Assay System from
Promega (Madison, WI, USA)
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and Data Analysis
C4-2B cells were treated with 8.0 μg/mL of EENL or
vehicle control for 24 and 48 h. Total RNA from each
biological replicate was isolated using Trizol (Invitrogen, San
Diego, CA) as per the manufacturer’s instructions. On-
column DNase treatment was performed followed by RNA
cleanup using RNeasy Mini kit (Qiagen, Valencia, CA)
according to the manufacture’s protocol as described pre-
viously (17). cDNA for each sample was synthesized by using
the high capacity cDNA archive kit (Applied Biosystems,
Foster City, CA). Complementary RNA was prepared,
labeled, and hybridized to Human Genome-U133-Plus2
oligonucleotide arrays (Affymetrix, Santa Clara, CA) repre-
senting >47,000 transcripts as described previously (17). The
experiments were performed in duplicate and the CEL ﬁles
were imported into Partek Genomics Suite software (Partek
Inc., St. Louis, MO), and data were normalized using the
Robust Multichip Averaging algorithm. One-way analysis of
variance (ANOVA) with nominal alpha value set to 0.05 was
used to determine probe sets signiﬁcantly different between
the EENL and vehicle-treated cells, followed by a Benjamini
and Hochberg Multiple testing correction to reduce the false
positive rate. These results were then separated by signiﬁcant
up-regulated or down-regulated genes, and used for further
validation. Differentially expressed genes were evaluated for
biologicalfunctionusingIngenuityPathwayAnalysis(Ingenuity,
Mountain View, CA).
Quantitative Real-Time PCR for Microarray Data Validation
To conﬁrm the differential expression of genes from
microarray data, we selected 40 up-regulated genes for
validation using custom TaqMan® Low Density Arrays in
C4-2B and PC-3M-luc2 cells. The arrays were preloaded with
gene-speciﬁc primers, FAM and MGB probes (Applied
Biosystems, Foster City, CA). The cDNA isolated as
described above was mixed with the Taqman universal master
mix (1:1) and loaded on to the microﬂuidic cards. The
reactions were performed in ABI 7900 HT system and the
quantity of cDNA was normalized using the housekeeping
gene GAPDH. mRNA levels were calculated as fold change
compared to control as described previously (18).
Protein Extraction and Western Blotting
C4-2B and PC-3M-luc2 cells were plated in 10-cm plates
and after reaching 60–70% conﬂuency, were treated for 24
and 48 h with EENL. Both the cell lines were treated with
two different concentrations, 45% (8.0 μg/mL for C4-2B and
20.0 μg/mL for PC-3M-luc2) and 55% (10 μg/mL for C4-2B
and 30 μg/mL for PC-3M-luc2) inhibitory concentrations of
EENL as determined by the viability assay. Proteins were
extracted from cells in modiﬁed RIPA buffer and western
blotting was performed using primary antibodies against
heme oxygenase-1 (HMOX1), aldo-keto reductases
AKR1C2, AKR1C3 and AKR1B10 from Abcam Inc.,
(Cambridge, MA) and horseradish peroxidase-conjugated
secondary antibodies as described previously (19). Immu-
nodetection was performed by LumiGLO chemiluminescence
detection system (Cell Signaling,Danvers,MA),inline with the
manufacturer’s instructions. GAPDH was used as loading
control.
Xenograft Tumor Growth
All experiments involving mice were conducted with the
approval of Executive Subcommittee of the Institutional
Animal Care and Use Committee of Mayo Clinic in
compliance with the Association for Assessment and Accred-
itation of Laboratory Animal Care International’s expect-
ations for animal care and use/ethics committees and the
investigators strictly followed the National Institutes of
Health guidelines for humane treatment of animals. Male
athymic nu/nu mice, 4–5 weeks of age, were obtained from
Charles River Laboratories (Wilmington, MA), and were
housed at the animal care facility as descried previously (16).
After acclimatization for 1 week, C4-2B and PC-3M-luc2 cells
(1.5×10
6 and 3.0×10
6 single cell suspension respectively, in
0.1 mL/mouse) suspended in 50% Matrigel in RPMI and
DMEM medium were injected subcutaneously on the left
ﬂank of the animals. The animals challenged with C4-2B and
PC-3M-luc2 cells were randomly assigned to three groups of
six each and two groups of six each, respectively. Animals
having palpable tumors after 2 weeks of challenge with
PC-3M-luc2 cells and 4 weeks of challenge with C4-2B cells,
were injected intraperitoneally with vehicle or EENL, 6 days
a week for 8 to 11 weeks. Animals in both the groups received
the same amount of vehicle (phosphate-buffered saline:
polyethylene glycol:DMSO+ethanol in 1:2:1 ratio) or leaf
extract+vehicle in 100 μL. Group 1 animals with C4-2B and
PC-3M-luc2 cells were vehicle controls. Group 2 and 3
animals with C4-2B cells were treated with 100 and
200 mg/kg body weight of EENL respectively. Group 2
animals with PC-3M-luc2 cells were treated with 200 mg/kg
body weight of EENL. The tumor volume of mice was
measured every week by external caliper measurements in
two dimensions and calculated as follows: length/2× width
2.
PC-3M-luc2 tumor growth was also monitored weekly using
IVIS imaging system (Caliper LifeSciences). Luciferin was
delivered intraperitoneally at 150 mg/kg in 200 μL and mice
were imaged 5 min post injection. Animals were weighed
once every week to monitor the effect of EENL toxicity on
body weight. At the end of the study, all the mice were killed
by CO2 inhalation; xenograft tumor tissue and the heart,
lungs, liver, kidneys, and spleen were excised, weighed, and
placed in phosphate-buffered formalin for ﬁxation and
hematoxylin and eosin (H&E) staining. Slides were stained
for DNA fragmentation using ApopTag peroxidase in situ
oligo ligation apoptosis detection kit (Millipore, Billerica,
MA) per manufacturer's protocol.
Determination of DHT Levels in the Tumor Tissues of Mice
DHT levels were measured in the EENL- and vehicle-
treated tumor tissues from mice as described (20). In brief,
prostatetumor tissues werethawed, weighed,andhomogenized
in 1.0 mL of phosphate-buffered saline. All samples were mixed
with deuterated stable isotope (d[4]-DHT) as internal standard
and then extracted with 5 mL of dichloromethane. Samples
werevortexed at a low speed, centrifugedat 3,000×g for 10 min;
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evaporated to dryness under nitrogen. This was followed by
conventional LC on a multiplexed liquid chromatography
system and analyzed on a tandem mass spectrometer equipped
with an electrospray interface. The inter-assay (n=24) %
coefﬁcient of variation was 18% at 53 pg/mL, 12.0% at
487 pg/mL, and 9% at 1,248 pg/mL
Statistical Analysis
Statistical analysis was carried out by using Student's t test,
one-way ANOVA, Fisher's exact test and Kruskal–Wallis
non-parametricANOVAbasedonrankswithaDunn'smultiple
comparison tests were used to compare the different exper-
imental groups. P value<0.05 was considered signiﬁcant. Fifty
percent inhibition concentration (IC50) values were calculated
by Probit regression. Partek Genomics suite 6.4 was used to
analyze the genomic data.
RESULTS
LC/TOF-MS Analysis of Neem Compounds in the EENL
LC/TOF-MS analysis was performed to identify the
potential active componentsintheEENL. Our analysis resulted
in mass spectral peaks that appear to match the calculated
masses of know neem leaf components including the 2′,3′-
dehydrosalannolstandard.ThetheoreticalmonoisotopicM+H
+
value for 2′,3′-dehydrosalannol is M+H
+1=555.2958 m/z
(molecular formula: C32H42O8). The observed 2′,3′-
dehydrosalannol standard showed a mass spectrum with a
major peak of 555.3055 m/z and retention time of 28.78 min.
The mass accuracy between the theoretical and the observed
monoisotopic peak for the 2′,3′-dehydrosalannol standard
is 17 ppm. The total ion chromatogram of the EENL
depicts seven signiﬁcant, based on intensity, peaks. The
three most intense peaks are labeled 1, 2, and 3; the
associated mass spectra to each peak is dominated by the
monoisotopic M+H
+1 values of 453.2364 m/z, 441.2342 m/z
and 555.3041 m/z, respectively. Peak 3 has a retention time
of 28.82 min, this is in agreement with the retention time
and observed mass between the 2′,3′-dehydrosalannol
standard and suggests this component of EENL is 2′,3′-
dehydrosalannol. The calculated monoisotopic mass (M+H
+1)
for the compound nimolinone (C30H44O3) is 453.3368 m/z,a n d
6-desacetyl nimbinene (C26H32O6) is 441.2277m/z.T h em a s s
accuracymeasurementsforthedominantmonoisotopic masses
observed for peaks 1 and 2, assuming that they are
suggestive of nimolinone and 6-deacetyl nimbinene, are
221 and 15 ppm, respectively. The EENL and 2′,3′-
dehydrosalannol standard were analyzed in duplicate,
representative chromatograms and spectra were shown
(Fig. 1).
EENL Inhibits the Growth of Prostate Cancer Cells in Vitro
In an initial approach to analyze the potential of whole
EENL for anticancer activity, we performed viability assays
employing 2 frequently used human androgen-refractory
C4-2B and PC-3M-luc2 prostate cancer cell lines. The
antiproliferative activity of EENL was measured by MTS
assay. Vehicle-treated cells were included as a control. EENL
exhibited adose-dependentinhibitionof C4-2Band PC-3M-luc2
cellgrowthoverabroadrangeofconcentrations(Fig.2), with an
IC50 of 9.0 and 25.0 μg/mL respectively, where IC50 is the
inhibition concentration at which a 50% inhibition of cell growth
is observed at 24 h of treatment.
EENL Alters the Gene Expression Profiles
To identify the molecular targets of the anticancer effects
of EENL, we performed high-resolution whole genome
proﬁling using an Affymetrix microarray platform. The gene
expression proﬁling of C4-2B prostate cancer cells treated
with EENL for 24 h showed signiﬁcant up-regulation of 191
genes and down-regulation of 97 genes (greater than
twofold), whereas the 48-h EENL-treated cells showed
signiﬁcant up-regulation of 129 genes and down-regulation
of 965 genes (greater than twofold). Using the Ingenuity
Pathways Knowledge Base, the dataset was used to map
independently up- and down-regulated genes for the
molecular and cellular functions. The most enriched
functions of the up-regulated genes are cell death, cellular
development, cellular growth and proliferation, lipid
metabolism, and small molecule biochemistry. The majority
of the up-regulated genes are associated with cell death
function which indicates that EENL could play a vital role
in promoting cell death. The most signiﬁcant down-
regulated gene functions are cell cycle, DNA replication,
recombination, and repair, cellular assembly and organization,
cellular movement, and gene expression. Greater than 70% of
the down-regulated genes are associated with cell cycle and
DNA replication, recombination, and repair functions which
indicate that EENL could play a signiﬁcant role in inhibition of
tumor growth.
To validate the observed changes in gene expression, we
chose 40 up-regulated genes for Taqman real-time PCR
analysis and analyzed in both C4-2B and PC-3M-luc2 prostate
cancer cells. For all genes tested, the direction of gene
expression change measured by RT-PCR and microarray
analysis agreed, although the magnitude of expression change
was not always the same using these 2 different analytical
methods. The RNA expression levels of 40 validated genes in
C4-2B cells treated with 8.0 μg/mL and PC-3M-luc2 cells
treated with 20.0 μg/mL of EENL for 24 and 48 h relatively
increased (Table I). These results support the ﬁndings
obtained from the microarray experiments. Though we only
validated up-regulated genes, we believe these results can
support the validity of down-regulated genes of our micro-
array data. The 40 most signiﬁcantly down-regulated genes
were shown from our microarray data of the C4-2B prostate
cancer cells after EENL treatment (Supplementary Table S1).
EENL Increases the Protein Expression Levels of HMOX1,
AKR1C2, AKR1C3, and AKR1B10
We selected four signiﬁcantly up-regulated genes to
conﬁrm the protein expression by Western blot analysis.
Our results revealed signiﬁcant increase of the HMOX1,
AKR1C2, AKR1C3 and AKR1B10 protein levels in C4-2B
and PC-3M-luc2 cells after 24 and 48 h of treatment with
EENL (Fig. 3). These results were consistent with the
368 Mahapatra et al.Fig. 1. Mass spectrometric analysis of the standard 2′,3′-dehydrosalannol and ethanol extract of neem leaves (EENL). a The total ion
chromatogram for the 2′,3′-dehydrosalannol shows a retention time of 28.85 min. a1 The mass spectrum of the 2′,3′-dehydrosalannol depict the
monoisotopic M+H
+1 ion at 555.3055 m/z. b The total ion chromatogram of EENL. b1 The mass spectrum of the peak 1, depict a monoisotopic
M+H
+1 ion at 458.2364 m/z, at a retention time of 27.32 min. This is possibly suggestive by mass alone as nimolinone. b2 The mass spectrum of
the peak 2, depict a monoisotopic M+H
+1 ion at 441.2342 m/z, at a retention time of 28.07 min. This is possibly suggestive by mass alone as 6-
desacetyl nimbinene. b3 The mass spectrum of the peak 3, depict a monoisotopic M+H
+1 ion at 555.3041 m/z, at a retention time of 28.75 min.
This is suggestive by mass and retention time as 2′,3′-dehydrosalannol. The difference between the measured value in the EENL and the
measured value from the 2′,3′-dehydrosalannol standard were <3 ppm with a difference in retention time of only 0.1 min
369 Anticancer Activity of Neem Leaf Extractincrease in the mRNA expression levels of the genes after
EENL treatment.
EENL Inhibits the Growth of Prostate Cancer Xenografts
in Nude Mice
To evaluate the antitumor efﬁcacy of EENL in vivo,w e
used xenograft tumor models. Immunodeﬁcient nu/nu mice
were subcutaneously injected with C4-2B and PC-3M-luc2
prostate cancer cells and were randomly divided into different
groups. The rates of xenograft tumor take for C4-2B and
PC-3M-luc2 cells were 100%. After 2 weeks of challenge with
PC-3M-luc2 cells and 4 weeks of challenge with C4-2B cells,
EENL was administered intraperitoneally. Tumor growth was
signiﬁcantly inhibited in all the EENL-treated groups.
Signiﬁcant inhibition of tumor size was observed in PC-3M-
luc2 (greater than ﬁvefold) and C4-2B (greater than tenfold)
tumor mice treated with 200 mg/kg body weight of the EENL
compared to the vehicle-treated mice (Fig. 4a–c). These
ﬁndings elucidate that EENL can suppress tumor growth.
There was no signiﬁcant change in body weight in any of the
groups after treatment which suggests that current EENL
extract causes no major toxicity to mice (Fig. 4d).
EENL Promotes Hyalinization and Apoptosis of the Tumor
Tissue
PC-3M-luc2 and C4-2B xenograft tumor mice were killed
at the end of 8 and 11 weeks of EENL treatment,
respectively. The tumor tissue and the other major organs
were collected and ﬁxed in phosphate-buffered formalin,
sectioned and stained with H&E to identify the histological
changes. Tumors were assessed histologically for ﬁbrosis,
coagulative tumor necrosis, and apoptosis. Mice treated with
EENL showed greater degree of ﬁbrosis and increased
apoptotic activity, whereas vehicle-treated group exhibited
greater amounts of coagulative tumor necrosis (Fig. 5). There
was no signiﬁcant change in the histology of the heart, lungs,
liver, kidneys and spleen after 8 or 11 weeks of EENL
treatment compared to vehicle-treated group which indicates
that EENL has no adverse effects on these vital organs.
Further, we demonstrated the presence of apoptotic cells in
the tumor tissue by ApopTag peroxidase staining. Xenograft
tumors in the control group of PC-3M-luc2 and C4-2B mice
had 0.58% and 0.62% of ApopTag cellular staining,
respectively, which increased to 3.8% (greater than sixfold)
and 4.77% (greater than sevenfold) in mice treated with
the EENL (Fig. 6). These results indicate that the possible
mechanism for regression is by inducing apoptosis of the
tumor cells.
EENL Suppresses the DHT Levels in the C4-2B Tumor
Tissues
PC-3M-luc2 and C4-2B xenograft tumor mice were
sacriﬁced at the end of 8 and 11 weeks of EENL treatment,
respectively. The tumor tissue and the other major organs
were snap-frozen in liquid nitrogen and stored at −80°C. The
DHT levels in the tumor tissues were analyzed using LC-MS
system as described (20). The DHT concentrations in C4-2B
tumor tissues of vehicle-treated mice were 1339±9.89
pg/100 mg (n=4). No DHT was detected in the PC-3M-luc2
tumor tissues of vehicle-treated mice and in the C4-2B and
PC-3M-luc2 tumor tissues of EENL-treated mice (n=4).
Fig. 2. Inhibition of prostate cancer cell proliferation by treatment with ethanol extract of neem leaves
(EENL). The antiproliferative effect of EENL on human prostate cancer cells C4-2B and PC-3M-luc2 was
evaluated by using the MTS viability assay. The cells were treated for 24, 48, and 72 h with varying
concentrations of EENL or vehicle as control. Experiments were performed in triplicate; data are
expressed as the mean±SD of the triplicate determinations of a representative experiment in % cell
viability of untreated cells (100%). *p<0.05
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In advanced castration recurrent prostate cancer, multiple
aberrant pathways can be potentially targeted for the therapeu-
tic effect that would yield better outcomes than monotherapies
(21). Neem contains multiple active compounds that work
simultaneously via different mechanisms (10–12). The scientiﬁc
evaluationofneemasananticanceragentislargelyunknown.We
usedEENLextracttoevaluatetheanticanceractivity.Analysisof
the components in the EENL revealed a total of seven peaks by
mass spectrometry (Fig. 1). The neem compounds 2′,3′-dehy-
drosalannol and 6-desacetyl nimbinene were reported before in
the neem leaves, whereas nimolinone was reported in the neem
ﬂowers (22). Our study suggests that 2′,3′-dehydrosalannol,
6-desacetyl nimbinene, and nimolinone were present as major
neem compounds in our EENL. In this study, we evaluated the
anticancer effects of EENL in castration-resistant C4-2B and
highly metastatic PC-3M-luc2 prostate cancer cells with an intent
to use the neem extract for locally advanced and metastatic
prostatecancerthatisassociatedwithconsiderablemorbidityand
mortality.
The extent of cell growth inhibition was measured by
MTS assay which was used to determine the number of viable
cells in proliferation. When various concentrations of EENL
were used for treatment, EENL showed different sensitiza-
tion potential; PC-3M-luc2 cells required higher concentra-
Table I. Up-regulation of mRNA Expression Levels of 40 Genes in C4-2B Cells Treated with 8.0 μg/mL and PC-3M-luc2 cells treated with
20.0 μg/mL of EENL for 24 and 48 h, Validated by Real-time PCR
Genes
C4-2B C4-2B PC-3M-luc2 PC-3M-luc2
Assay ID Function 24 h 48 h 24 h 48 h
ABCG1 3.1±0.5 3.0±1.4 3.4±0.8 4.4±1.7 Hs01555190_g1 Nucleotide binding
AKR1B10 19.2±6.6 96.5±26.8 19.7±4.6 31.1±2.3 Hs00252524_m1 Aldo-keto reductase activity
AKR1C2 39.4±14.2 30.8±12.3 29.5±6.1 57.0±11.5 Hs00413886_m1 Oxidoreductase activity
AKR1C3 15.1±6.6 16.8±4.6 9.9±1.5 37.6±5.6 Hs00366267_m1 Oxidoreductase activity
ALDH3A2 7.5±2.5 4.1±2.8 1.1±1.1 9.1±2.9 Hs00166066_m1 Aldehyde dehydrogenase
ALOX5 2.9±0.7 3.1±1.1 2.6±0.8 4.6±1.0 Hs01095330_m1 Lipoxygenase activity
ATF3 4.7±2.8 2.9±0.1 6.2±1.4 19.4±3.5 Hs00231069_m1 Transcription factor
CDKN1A 6.0±2.7 5.1±1.1 5.0±1.2 10.4±2.3 Hs00355782_m1 Protein kinase inhibitor
CHAC1 4.5±2.8 2.9±0.2 5.2±1.5 8.5±3.3 Hs00225520_m1 Protein binding
CLU 2.6±0.5 2.1±1.2 2.7±1.2 2.1±0.7 Hs00156548_m1 Protein binding
CLEC7A 2.3±1.1 1.5±2.0 2.5±0.2 4.6±2.7 Hs00224028_m1 Opsonin binding
CSTA 4.3±2.7 2.2±0.3 2.9±0.5 2.9±0.2 Hs00193257_m1 Protease binding
CYP1A1 17.2±5.2 14.2±4.1 3.0±0.2 8.1±1.3 Hs01054797_g1 Monooxygenase activity
CYP1A2 5.0±3.1 14.5±2.0 2.7±0.1 3.6±0.8 Hs01070374_m1 Steroid catabolism
DDIT3 6.0±3.0 3.6±0.6 3.7±1.2 12.3±1.8 Hs00358796_g1 Nucleic acid binding
DMRT1 8.6±4.1 5.1±2.5 4.9±0.2 2.6±1.3 Hs00232766_m1 Transcription factor
DNAJB9 2.1±0.2 1.5±1.8 4.1±1.9 20.7±4.7 Hs01052402_m1 Protein binding
EGR1 5.3±1.1 2.1±1.1 2.4±0.8 15.4±4.0 Hs00152928_m1 Transcription factor
FOXC1 4.3±0.4 3.0±1.0 1.6±1.0 12.1±1.9 Hs00559473_s1 Transcription factor
FTH1 7.8±3.0 4.5±3.1 1.7±1.2 17.7±3.7 Hs01694011_s1 Ferroxidase activity
GCLM 8.2±3.6 7.0±2.2 3.9±0.1 4.3±0.4 Hs00157694_m1 Glutamate-cysteine ligase
GPNMB 4.5±1.2 2.1±2.2 3.2±1.1 1.6±1.5 Hs01095669_m1 Integrin binding
HINT3 2.2±1.5 2.2±0.6 2.8±0.7 3.4±0.5 Hs00370872_m1 Catalytic activity
HMOX1 15.7±5.0 17.9±4.1 62.1±10.5 80.0±16.6 Hs01110251_m1 Heme oxygenase activity
LAMP3 67.6±18.9 31.0±4.9 2.9±0.4 2.1±0.9 Hs00180880_m1 Integral to membrane
LY96 6.4±0.7 3.6±0.3 3.6±0.4 6.5±2.3 Hs00209771_m1 Receptor activity
MALAT1 2.9±1.1 2.2±0.1 4.3±1.1 16.4±2.1 Hs00273907_s1 Nucleotide binding
MDM2 3.1±2.0 1.6±0.9 1.9±0.8 1.9±0.7 Hs01066930_m1 p53 binding
NQO1 2.3±0.1 3.4±1.0 1.3±1.7 5.3±1.9 Hs00168547_m1 NADPH dehydrogenase
S100P 3.7±0.1 1.4±1.0 2.1±1.1 5.2±2.7 Hs00195584_m1 Calcium-dependent protein
SESN2 4.1±2.1 2.2±0.3 3.5±0.5 2.5±0.8 Hs00230241_m1 Cell cycle arrest
SERPINB5 7.6±3.5 3.7±1.6 1.4±0.8 7.5±1.0 Hs00184728_m1 Enodeptidase inhibitor
SLC7A11 4.7±0.2 2.1±1.2 2.9±0.2 4.4±2.6 Hs00204928_m1 Transporter activity
SPINK1 1.4±1.3 2.8±0.9 4.7±2.2 10.8±3.4 Hs00162154_m1 Enodeptidase inhibitor
SPRR1A 10.0±4.2 4.8±1.9 4.7±1.1 2.0±0.1 Hs00954595_s1 Structural molecule
TRIM16 2.8±0.1 3.0±1.0 3.4±0.9 13.8±2.2 Hs00414879_m1 DNA binding
TUBA1A 5.5±2.2 3.2±1.2 1.8±1.2 2.6±0.6 Hs00362387_m1 Structural molecule
TXNRD1 3.7±1.1 1.5±0.1 2.0±1.9 11.3±3.3 Hs00182418_m1 Thioredoxin reductase
WDR19 2.6±0.4 2.2±0.4 1.1±0.5 10.7±0.2 Hs00228414_m1 Transmembrane signaling
ZNF143 1.8±1.9 1.3±1.6. 2.8±1.6 21.9±5.5 Hs00185689_m1 Transcription factor
The endogenous GAPDH mRNA levels were measured as internal controls. The experiments were performed in triplicate; mean±SD of the fold
increase in the expression levels of genes compared with the respective controls were shown. Assay ID’s of the genes used for validation were from
Applied Biosystems
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EENL treatment signiﬁcantly inhibited the growth of both
C4-2B and PC-3M-luc2 cells (Fig. 2). To unravel the
molecular targets involved in mediating the effect of EENL
on prostate cancer cells, we used genome-wide microarray
analysis. C4-2B prostate cancer cells treated with EENL
showed a signiﬁcant deregulation of 288 genes that increased
to 1094 genes after 48 h. We further validated the expression
of 40 signiﬁcantly up-regulated genes by quantitative PCR in
C4-2B and PC-3M-luc2 prostate cancer cells. PCR results
were consistent with the microarray data. There was a
signiﬁcant up-regulation of the genes associated with the
cell-to-cell signaling, cell death functions, drug metabolism
and oxidative stress response (Table I), suggesting that the
EENL is promoting cell death of the prostate cancer cells.
Most of these up-regulated genes have been previously shown
to be down-regulated in human prostate cancer tissues using
microarray analysis (18,23–26). The RNA expression proﬁles
of the 40 most signiﬁcantly down-regulated genes were shown
from our microarray analysis (Supplementary Table S1). All
these40 down-regulated genes werefound to beup-regulated in
various cancer tissues as shown in the Oncomine microarray
data base (27). Most of the down-regulated genes ANLN,
ASPM, ATAD2, ATRX, BMPR2, CDC2, CENPF, COL12A1,
DLGAP5, DSG2, DTL, GUCY1A3, HELLS, HIST1H4C,
HMMR, HNRNPA2B1, HSP90B1, KIF11, KIF14, NRIP1,
NUF2, PHLDA1, SFPQ, SMC2, SMC3, SMC4, STAG2, TFPI,
TOP2A, TPR, ZAK,a n dZNF638 were involved in cell cycle,
cellular assembly and organization, DNA replication, recombi-
nation, and repair functions (26,27), which implicates the role of
EENL in the control of tumor cell proliferation.
We further focused on 4 genes HMOX1, AKR1C2,
AKR1C3,a n dAKR1B10 for validation of protein expres-
sion levels. HMOX1, the inducible isoform is a rate-
limiting enzyme in heme degradation (28,29). HMOX1 is
an important homeostatic factor with pleiotropic effects
against metabolic immune/inﬂammatory and angiogenesis
(30–33). Over-expression of HMOX1 decreased the inva-
sive potential of prostate cancer cells by down-regulating
MMP9 expression (34). Our results revealed a highly
signiﬁcant increase in the RNA and protein expression
levels of HMOX1 following EENL treatment of both C4-
2B and PC-3M-luc2 cells (Table I and Fig. 3). Induction of
HMOX1 expression through EENL could be a promising
strategy to treat prostate cancer.
Numerous studies have focused on the androgen abla-
tion, by decreased testosterone synthesis and blockade of
androgen receptor, as the major treatment for hormone-
sensitive prostate cancer (35,36). Despite the androgen
deprivation therapy in prostate cancer patients, prostatic
DHT levels were found to be 25% of the pretreatment levels
(37). Steady-state levels of intracellular DHT are maintained
through a balance between local synthetic and catabolic rates.
However, little emphasis has been placed on the importance
of DHT catabolism in the prostate. AKRs are phase I drug-
metabolizing enzymes for a variety of carbonyl-containing
drugs (38). Compared to the paired benign tissues, prostate
cancer tissues showed a reduced metabolism of DHT which
corresponded with a loss of AKR1C2 expression (39).
Transient expression of AKR1C2 reduced DHT-stimulated
proliferation of LAPC-4 prostate cancer cells (40). AKR1C2
andAKR1C3reduced5α-DHTtoyieldeither3α-andostanediol
(an inactive androgen) or 3β-androstanediol (a proapoptotic
ligand for ERβ; 41). Cellular proliferation experiments showed
that increased AKR1C2 expression can reduce DHT-stimulated
cell growth, and increased metabolism of DHT can block the
activation of AR (13). Thus, androgen catabolism can
indirectly regulate the activity of AR and thereby provides
new therapeutic targets for the treatment of prostate
cancer. The over-expression of AKR1B10 was reported in
early stages of well and moderately differentiated tumors
and down-regulation in advanced tumor-stages with low
grade of differentiation, implicating that AKR1B10 may be
a helpful marker for differentiation (42). Our results
revealed highly signiﬁcant up-regulation in the RNA and
protein expression levels of AKR1C2, AKR1C3,a n d
AKR1B10 with EENL treatment (Table I and Fig. 3).
The increase in AKRs could contribute to the suppression
of DHT levels observed in the C4-2B tumor tissues of
EENL-treated mice. No DHT was detected in the PC-3M-
luc2 tumors which supports previous ﬁnding that PC-3 cells do
not express 5-reductase type II for conversion of testosterone to
DHT (43).Wespeculatethatup-regulation of AKRsexpression
with EENL treatment could inhibit cellular proliferation by
inducing apoptosis and reduce the tumor growth. Further
Fig. 3. Over-expression of HMOX1, AKR1C2, AKR1C3 and AKR1B10 in C4-2B and PC-
3M-luc2 prostate cancer cells after treatment with ethanol extract of neem leaves (EENL)
for 24 and 48 h. Protein levels were measured with speciﬁc antibodies by Western blot
analysis; GAPDH was the loading control. Vehicle-treated cells were used as control. The
experiments were repeated thrice and the representative blot was shown
372 Mahapatra et al.studies are required to evaluate the role of EENL induced
AKRs on the DHT catabolism in prostate cancer cells.
We further evaluated the antitumor effect of the EENL
using the xenograft prostate cancer models.
In mice injected with PC-3M-luc2 metastatic prostate
cancer cells (3.0×10
6 cells) maximum tolerable xenograft
tumor growth was attained by 8 weeks of administration,
whereas in mice injected with C4-2B cells (1.5×10
6 cells) the
Fig. 4. Ethanol extract of neem leaves (EENL) inhibits the growth of human C4-2B and PC-3M-luc2
prostate cancer xenografts in nude mice. Male nu/nu mice were challenged with subcutaneous injection of
C4-2B and PC-3M-luc2 cells. The animals challenged with C4-2B and PC-3M-luc2 cells were randomly
assigned to three groups of six each and two groups of six each, respectively. After 2 weeks of challenge
with PC-3M-luc2 cells and 4 weeks of challenge with C4-2B cells the animals were injected intra-
peritoneally with vehicle control or 100 or 200 mg/kg body weight of EENL, 6 days a week. Results depict
mean tumor volume±SEM from 6 mice of each group with a C4-2B xenografts and b PC-3M-luc2
xenografts. c Representative IVIS image of control and treated mice with PC-3M-luc2 tumors after
8 weeks. Luciferin was delivered intraperitoneally and mice were imaged 5 min post injection. d Body
weight changes of tumor bearing mice with (A) C4-2B xenografts and (B) PC-3M-luc2 xenografts
(n=6 per group). *p<0.05
373 Anticancer Activity of Neem Leaf Extractxenograft tumor growth with was relatively slow and attained
maximum tolerable tumor growth by 11 weeks. Our studies
revealed that administration of EENL signiﬁcantly
suppressed the tumor growth (Fig. 4). The most signiﬁcant
histological difference between EENL- and vehicle-treated
mice were the presence of hyalinized ﬁbrosis (Fig. 5). We
believe this hyalinization is a feature of tumor regression.
Also, the control mice exhibited a greater amount of
Fig. 4. (continued)
Fig. 5. Histological changes of C4-2B tumor tissues of mice treated with ethanol extract of neem leaves
(EENL; 100 μg/kg body weight). At the end of 11 weeks, xenograft tumor tissue was collected from the
mice and stained with hematoxylin and eosin. Two sections of tumor tissue from each mouse and six mice
in a group were examined for histological changes. a Control tumor tissue from vehicle-treated mice shows
dense tumor cells and the arrow points to the area of coagulative tumor necrosis at ×100. b–f Depicts
tumor tissues from mice treated with EENL. b Tumor tissue shows nests of tumor cells separated by
hyalinized connective tissue indicated by arrow at 100×, indication of treatment effect. c Tumor
hyalinization showing apoptosis, the thin and thick arrows indicate apoptotic bodies and pyknotic nucleus
undergoing cell death at ×400. d Tumor hyalinization showing apoptotic nucleus at ×600. e Tumor tissue
with hyalinized ﬁbrosis, arrow indicates residual tumor at ×100. f Hyalinized ﬁbrous tissue showing residual
tumor cells at ×200 magniﬁcation
374 Mahapatra et al.coagulative tumor necrosis, a feature typical of rapidly
growing malignancies. Additional studies are necessary in
large numbers of cases to further characterize these
histological changes. It has been reported that ﬁbrous tissue
is related to decreased tumor invasiveness and is an indicator
of improved survival after resection (44,45). These results are
important to beexplored further in thehuman clinical trials. We
have demonstrated that reduction of tumor growth in mice is
associated with apoptosis of tumor cells (Fig. 6). There was no
signiﬁcant change in either body weight or histology of any
major organs in the EENL-treated group compared to control
group, which conﬁrms that EENL at 100 and 200 mg/kg body
weight has no adverse effects (46,47). The dose administered in
the present study (200 mg/kg body weight) was based on
previous reports (48,49). This dose is also far less than the oral
median lethal dose LD50 for EENL, which was found to be
4.57g/kgbodyweightinacutetoxicitystudies(50).Wespeculate
thatneem,withitslowriskoftoxicity,couldbesafelyusedinthe
prostate cancer prevention and treatment trials.
In summary, we demonstrated that EENL-containing
natural bioactive compounds 2′,3′-dehydrosalannol, 6-desacetyl
nimbinene, and nimolinone inhibited in vitro cell prolifer-
ation and in vivo tumor growth. For the ﬁrst time, we used
genome-wide proﬁling approach to identify the genes
associated with multiple biological pathways as potential
targets of the antitumor activity of EENL and demonstra-
ted the up-regulation of the HMOX1 and AKR protein
changes. This is the ﬁrst study to evaluate the antitumor
effect of EENL in the preclinical models of prostate
cancer. Our data suggests that the deregulated genes
identiﬁed in our expression proﬁling could play an
important role in the inhibition of tumor growth with the
formation of hyalinized ﬁbrous tissue. Further studies are
required to unravel the role of these individual compounds
in the EENL on tumor growth. The molecular targets
identiﬁe di no u rs t u d ym a yb ee x p loited for devising
mechanism-based chemopreventive or therapeutic strat-
egies for prostate cancer.
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